---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Expected outcomes of therapy"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Expected outcomes of therapy. Topics: Guideline treatment goals: PASI 75 minimum and PASI 90, absolute PASI below 2, or DLQI of 1 or less as the desired goal; Treat-to-target response thresholds: BSA of 1% or less at 3 months and every 6 months; Time to response and timing of the treatment goal assessment; Quality of life and symptom resolution at PASI 90, PASI 95, and PASI 100; 2 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
- Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
- Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
- Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
- Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/); [Papp et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354354/); [Augustin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480266/); [Papp et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/); [Bissonnette et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175198/)

<a id="topic-2.2.2.7-2"></a>

### Guideline treatment goals: PASI 75 minimum and PASI 90, absolute PASI below 2, or DLQI of 1 or less as the desired goal

> “The fundamental goal of any therapy is to achieve complete clearance of symptoms – that is, the absence of cutaneous symptoms of psoriasis.”
> “However, this goal is not realistically achievable in all patients at this time.”
> “At the end of the induction period, a PASI 75 response is the minimum target, which should be controlled for at regular intervals during the course of treatment.”
> “Reaching a PASI 90 response or an absolute PASI <2 or DLQI ≤ 1 should be the desired treatment goal.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.7-3"></a>

### Treat-to-target response thresholds: BSA of 1% or less at 3 months and every 6 months

> “The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline.”
> “The target response at 3 months postinitiation was BSA 1% or less.”
> “The target response at every 6 months maintenance evaluation is BSA 1% or less.”

Source: [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/)

<a id="topic-2.2.2.7-4"></a>

### Time to response and timing of the treatment goal assessment

> “For treatments with a fast onset of action, treatment goals should be controlled for at the end of the induction therapy after 10 to 12 weeks; for treatments with a slower onset of action, this should be done after 16 to 24 weeks.”
> “These time frames may not always include the time of maximum therapeutic effect.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

> “Forty-five trials were included in the main analyses.”
> “The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks.”
> “This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks.”
> “Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors.”

Source: [Papp et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354354/)

<a id="topic-2.2.2.7-5"></a>

### Quality of life and symptom resolution at PASI 90, PASI 95, and PASI 100

> “Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE.”
> “Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively).”
> “Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%).”

Source: [Augustin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480266/)

<a id="topic-2.2.2.7-6"></a>

### Durability with continuous risankizumab through week 304

> “Of 897 patients enrolled in the LIMMitless study, 661 completed the study for a total of 4921.2 patient years of exposure to risankizumab.”
> “At week 304, 86.0% of patients achieved PASI 90, 54.2% achieved PASI 100, 84.7% achieved sPGA 0/1, and 76.3% achieved DLQI 0/1 (using modified nonresponder imputation).”

Source: [Papp et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/)

<a id="topic-2.2.2.7-7"></a>

### Durability with continuous secukinumab 300 mg through year 5

> “At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment.”
> “PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%).”
> “DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5).”

Source: [Bissonnette et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175198/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
